About PHA Staff

This author has not yet filled in any details.
So far PHA Staff has created 236 blog entries.

Notice: PHA Phone Systems Experiencing Intermittent Outages

The Pulmonary Hypertension Association (PHA) office phone system is experiencing intermittent outages as of Friday, Feb. 16, 2018 at 9:45 a.m. EST. We are working on a solution as quickly as possible. If you need to contact PHA with general inquiries about membership, Conference, store orders or other questions, and are unable to reach us

2018-02-16T17:49:43+00:00 February 16th, 2018|

PHA Accreditation Program Assures Access to Specialized Care for Thousands With Often-Misdiagnosed Deadly Lung Disease

Silver Spring, MD (February 15, 2018) – A national accreditation program launched by the Pulmonary Hypertension Association (PHA) assures that more than 12,000 people with a life-threatening lung disease are getting care from clinicians who specialize in their often-misdiagnosed condition. Pulmonary hypertension (PH), also known as high blood pressure of the lungs, affects adults

2018-02-16T16:07:20+00:00 February 16th, 2018|

Seeking Financial Assistance Because of Caring Voice Developments? Previous CVC Clients Should Make That Clear When Contacting Manufacturers.

In January, the Department of Health and Humans Services informed companies that manufacture PH medications that they would be permitted to provide one year of free medication to some individuals who received assistance from the Caring Voice Coalition as of Nov. 28, 2017. To be eligible, a PH patient must have health insurance through a

2018-02-16T16:16:51+00:00 February 16th, 2018|

Adding Immunoadsorption to Current Treatment for People With IPAH

Study looks at a theory that adding immunoadsorption, or the process of filtering out antibodies from the blood, in addition to other PH therapies may help improve outcomes for people with idiopathic pulmonary arterial hypertension. by Phyllis Hanlon, Contributing Writer   People with idiopathic pulmonary arterial hypertension (IPAH), a type of WHO Group 1 PH (PAH,

2018-02-15T18:13:05+00:00 February 15th, 2018|

An Overview of Pulmonary Arterial Hypertension (PAH) and Lupus

WHO Group 1 PH (PAH, pulmonary arterial hypertension) can appear by itself of be associated with other medical conditions including connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). Although CTD-associated PAH is very common in people who have PAH, PAH is extremely uncommon among the many people with SLE. Because of this, a

2018-02-09T03:24:39+00:00 February 9th, 2018|

Specialty Pharmacy Update on National Shortage of Diluent Used for Some PH Medications

PHA was recently made aware of a national shortage of the diluent used for mixing some PH medications. The shortage is a result of product manufactures who have been affected by the 2017 hurricane season. The specialty pharmacies that deliver PH medications are working to monitor available supplies and purchase as much inventory as possible.

2018-02-15T18:50:05+00:00 February 2nd, 2018|

Researchers: Collect Data at Unique Opportunity in PH Field

Investigator Applications are now being accepted for the Research Room at PHA’s 2018 International PH Conference and Scientific Sessions. The Research Room helps researchers further their studies by providing the opportunity for collection of data, including phenotypic information and biological specimens, from the largest gathering of pulmonary hypertension patients in the world. Impact the field

2018-02-01T17:37:14+00:00 February 1st, 2018|

Treating Pulmonary Hypertension Associated With Connective Tissue Disease

by Phyllis Hanlon, Contributing Writer  WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a progressive and chronic disease. There currently is no cure. In PAH, the arteries in the lungs become narrow, thickened or stiff, which causes high blood pressure in the lungs. The disease can present in several forms, one of which

2018-01-31T22:16:23+00:00 January 31st, 2018|

Webinar for Medical Professionals CTEPH: Finding, Treating and Future Directions

Friday, February 9th, 2018, 3:00 p.m. ET Josanna M. Rodriguez-Lopez, M.D., Massachusetts General Hospital This webinar will focus on WHO Group 4 pulmonary hypertension (PH), chronic thromboembolic pulmonary hypertension (CTEPH), and will include information about what makes CTEPH unique from other types of PH and why it is important to rule out CTEPH in

2018-02-09T03:44:57+00:00 January 31st, 2018|

Legislation Passed to “Recognize, Assist, Include, Support and Engage” Family Caregivers

On Monday, January 15, 2018, President Trump signed into law the Recognize, Assist, Include, Support and Engage (RAISE) Family Caregivers Act calling for a national strategy to address the needs of family caregivers. This bipartisan legislation directs the Department of Health and Human Services (HHS) to develop and make publicly available a National Family Caregiving Strategy that identifies recommended actions

2018-01-31T20:11:57+00:00 January 31st, 2018|